Copyright Reports & Markets. All rights reserved.

Global Oncology Biosimilars Market Research Report 2021

Request for Sample of this report
Buy now

1 Oncology Biosimilars Market Overview

  • 1.1 Product Overview and Scope of Oncology Biosimilars
  • 1.2 Oncology Biosimilars Segment by Type
    • 1.2.1 Global Oncology Biosimilars Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Monoclonal Antibody
    • 1.2.3 Hematopoietic Agents
    • 1.2.4 G-CSF
    • 1.2.5 Others
  • 1.3 Oncology Biosimilars Segment by Application
    • 1.3.1 Oncology Biosimilars Sales Comparison by Application: (2021-2027)
    • 1.3.2 Retail Pharmacies
    • 1.3.3 Hospital Pharmacy
    • 1.3.4 Online Pharmacy
  • 1.4 Global Oncology Biosimilars Market Size Estimates and Forecasts
    • 1.4.1 Global Oncology Biosimilars Revenue 2016-2027
    • 1.4.2 Global Oncology Biosimilars Sales 2016-2027
    • 1.4.3 Oncology Biosimilars Market Size by Region: 2016 Versus 2021 Versus 2027

2 Oncology Biosimilars Market Competition by Manufacturers

  • 2.1 Global Oncology Biosimilars Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Oncology Biosimilars Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Oncology Biosimilars Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Oncology Biosimilars Manufacturing Sites, Area Served, Product Type
  • 2.5 Oncology Biosimilars Market Competitive Situation and Trends
    • 2.5.1 Oncology Biosimilars Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Oncology Biosimilars Players Market Share by Revenue
    • 2.5.3 Global Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Oncology Biosimilars Retrospective Market Scenario by Region

  • 3.1 Global Oncology Biosimilars Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Oncology Biosimilars Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Oncology Biosimilars Market Facts & Figures by Country
    • 3.3.1 North America Oncology Biosimilars Sales by Country
    • 3.3.2 North America Oncology Biosimilars Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Oncology Biosimilars Market Facts & Figures by Country
    • 3.4.1 Europe Oncology Biosimilars Sales by Country
    • 3.4.2 Europe Oncology Biosimilars Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Oncology Biosimilars Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Oncology Biosimilars Sales by Region
    • 3.5.2 Asia Pacific Oncology Biosimilars Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Oncology Biosimilars Market Facts & Figures by Country
    • 3.6.1 Latin America Oncology Biosimilars Sales by Country
    • 3.6.2 Latin America Oncology Biosimilars Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Oncology Biosimilars Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Oncology Biosimilars Sales by Country
    • 3.7.2 Middle East and Africa Oncology Biosimilars Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 U.A.E

4 Global Oncology Biosimilars Historic Market Analysis by Type

  • 4.1 Global Oncology Biosimilars Sales Market Share by Type (2016-2021)
  • 4.2 Global Oncology Biosimilars Revenue Market Share by Type (2016-2021)
  • 4.3 Global Oncology Biosimilars Price by Type (2016-2021)

5 Global Oncology Biosimilars Historic Market Analysis by Application

  • 5.1 Global Oncology Biosimilars Sales Market Share by Application (2016-2021)
  • 5.2 Global Oncology Biosimilars Revenue Market Share by Application (2016-2021)
  • 5.3 Global Oncology Biosimilars Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Celltrion
    • 6.1.1 Celltrion Corporation Information
    • 6.1.2 Celltrion Description and Business Overview
    • 6.1.3 Celltrion Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Celltrion Product Portfolio
    • 6.1.5 Celltrion Recent Developments/Updates
  • 6.2 Biocon
    • 6.2.1 Biocon Corporation Information
    • 6.2.2 Biocon Description and Business Overview
    • 6.2.3 Biocon Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Biocon Product Portfolio
    • 6.2.5 Biocon Recent Developments/Updates
  • 6.3 Dr. Reddy’s Laboratories
    • 6.3.1 Dr. Reddy’s Laboratories Corporation Information
    • 6.3.2 Dr. Reddy’s Laboratories Description and Business Overview
    • 6.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Dr. Reddy’s Laboratories Product Portfolio
    • 6.3.5 Dr. Reddy’s Laboratories Recent Developments/Updates
  • 6.4 STADA Arzneimittel AG
    • 6.4.1 STADA Arzneimittel AG Corporation Information
    • 6.4.2 STADA Arzneimittel AG Description and Business Overview
    • 6.4.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 STADA Arzneimittel AG Product Portfolio
    • 6.4.5 STADA Arzneimittel AG Recent Developments/Updates
  • 6.5 Intas Pharmaceuticals
    • 6.5.1 Intas Pharmaceuticals Corporation Information
    • 6.5.2 Intas Pharmaceuticals Description and Business Overview
    • 6.5.3 Intas Pharmaceuticals Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Intas Pharmaceuticals Product Portfolio
    • 6.5.5 Intas Pharmaceuticals Recent Developments/Updates
  • 6.6 Pfizer
    • 6.6.1 Pfizer Corporation Information
    • 6.6.2 Pfizer Description and Business Overview
    • 6.6.3 Pfizer Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Pfizer Product Portfolio
    • 6.6.5 Pfizer Recent Developments/Updates
  • 6.7 Sandoz International
    • 6.6.1 Sandoz International Corporation Information
    • 6.6.2 Sandoz International Description and Business Overview
    • 6.6.3 Sandoz International Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Sandoz International Product Portfolio
    • 6.7.5 Sandoz International Recent Developments/Updates
  • 6.8 Teva Pharmaceutical Industries Ltd
    • 6.8.1 Teva Pharmaceutical Industries Ltd Corporation Information
    • 6.8.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
    • 6.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Teva Pharmaceutical Industries Ltd Product Portfolio
    • 6.8.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
  • 6.9 Apotex
    • 6.9.1 Apotex Corporation Information
    • 6.9.2 Apotex Description and Business Overview
    • 6.9.3 Apotex Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Apotex Product Portfolio
    • 6.9.5 Apotex Recent Developments/Updates
  • 6.10 BIOCAD
    • 6.10.1 BIOCAD Corporation Information
    • 6.10.2 BIOCAD Description and Business Overview
    • 6.10.3 BIOCAD Oncology Biosimilars Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 BIOCAD Product Portfolio
    • 6.10.5 BIOCAD Recent Developments/Updates

7 Oncology Biosimilars Manufacturing Cost Analysis

  • 7.1 Oncology Biosimilars Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Oncology Biosimilars
  • 7.4 Oncology Biosimilars Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Oncology Biosimilars Distributors List
  • 8.3 Oncology Biosimilars Customers

9 Oncology Biosimilars Market Dynamics

  • 9.1 Oncology Biosimilars Industry Trends
  • 9.2 Oncology Biosimilars Growth Drivers
  • 9.3 Oncology Biosimilars Market Challenges
  • 9.4 Oncology Biosimilars Market Restraints

10 Global Market Forecast

  • 10.1 Oncology Biosimilars Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Oncology Biosimilars by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Oncology Biosimilars by Type (2022-2027)
  • 10.2 Oncology Biosimilars Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Oncology Biosimilars by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Oncology Biosimilars by Application (2022-2027)
  • 10.3 Oncology Biosimilars Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Oncology Biosimilars by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Oncology Biosimilars by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Monoclonal Antibody
    Hematopoietic Agents
    G-CSF
    Others

    Segment by Application
    Retail Pharmacies
    Hospital Pharmacy
    Online Pharmacy

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    U.A.E

    By Company
    Celltrion
    Biocon
    Dr. Reddy’s Laboratories
    STADA Arzneimittel AG
    Intas Pharmaceuticals
    Pfizer
    Sandoz International
    Teva Pharmaceutical Industries Ltd
    Apotex
    BIOCAD

    Buy now